BioMarin to acquire Amicus Therapeutics for $4.8 billion
found
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Amicus
since
auto-detected in 1 stories
22 hours ago
page 1 of 1